Protocol Ledger

NCT05601440 · Phase II · RECRUITING

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Interventional Phase II clinical trial protocol NCT05601440 sponsored by Canadian Cancer Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-13 Enrollment: 484 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05601440
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)484 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05601440
Protocol FieldVerified Registry Value
NCT IdentifierNCT05601440
Consolidated Lead SponsorCanadian Cancer Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment484 participants (ESTIMATED)
Registered Start Date2023-06-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05601440
Hospital Research SiteLocationSite Profile
Arthur J E Child Comprehensive Cancer CentreCalgary, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI